Kidney Cancer
Conditions
Interventions
experimental group:immunocheckpoint inhibitors
control group:Nil
Sponsors
The Second Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 18 year-old 6 months; 7. Adequate organ function, defined as following criteria: a. Platelets 75 x 109/L, Hemoglobin 10.0 g/L, Absolute Neutrophils(ANC) >= 1.5x10^9/L; b. Serum bilirubin = 30 ml/min. 8. Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by multigated acquisition (MUGA) scan or echocardiography; 9. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion criteria
Exclusion criteria: 1. Histologically diagnosed as undifferentiated carcinoma, sarcoma, collecting duct carcinoma and lymphoma; 2. NCICTCAE Grade 3 bleeding in 4 weeks before inclusion; 3. Diagnosed as any second primary malignant tumor in 5 years before inclusion, except for basal cell carcinoma, Squamous cell carcinoma of the skin, or cervical carcinoma in situ without evidence of recurrence for at least 12 months through adequate treatment; 4. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within 7 days before randomization and at first day of every cycle on visit; 5. Other severe acute or chronic physiologicalor psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study; 6. Current treatment on another clinical trial. Supportive care or non-therapeutic clinical trials are allowed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating tumor cells in peripheral blood;recurrence-free survival ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Countries
China
Contacts
Public ContactWang Zhenlong
The Second Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed